歡迎來(lái)到上海通蔚！

021-54845833/15800441009

品質(zhì)保證 · 通蔚試劑

當(dāng)前位置: 首頁(yè) > 科研產(chǎn)品 > 科研抗體 > 一抗 > 小鼠抗CCAR2單克隆抗體

產(chǎn)品中心

  • 小鼠抗CCAR2單克隆抗體

    規(guī)格：
    數(shù)量：

    購(gòu)買(mǎi)數(shù)量

    價(jià)格：￥
    • 品牌 : 通蔚生物
    • 目錄號(hào) : TW6535
    • 應(yīng)用 : 僅限于科研使用
    • 保存條件 : 低溫保存
    • 貨期 : 現(xiàn)貨
    • 商品庫(kù)存：40
  • 商品詳情
  • 參考文獻(xiàn)
  • 說(shuō)明書(shū)下載
  • 商品評(píng)論0
  • 相關(guān)產(chǎn)品

中文名稱(chēng)：小鼠抗CCAR2單克隆抗體

英文名稱(chēng)： Anti-CCAR2 mouse monoclonal antibody
別      名： cell cycle and apoptosis regulator 2; DBC1; DBC-1; NET35; p30DBC; p30 DBC; KIAA1967
相關(guān)類(lèi)別： 一抗

儲(chǔ)       存： 冷凍（-20℃）
宿       主： Mouse

抗       原： CCAR2
反應(yīng)種屬： Human, Mouse, Rat, Monkey
標(biāo)  記  物： Unconjugate

克隆類(lèi)型： Mouse Monoclonal
技術(shù)規(guī)格

Background:

Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions. Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis. Inhibits SUV39H1 methyltransferase activity. As part of a histone H3-specific methyltransferase complex may mediate ligand-dependent transcriptional activation by nuclear hormone receptors. Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress. Regulates the circadian expression of the core clock components NR1D1 and ARNTL/BMAL1. Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:18235501, PubMed:18235502, PubMed:19131338, PubMed:19218236, PubMed:22446626, PubMed:23352644, PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978).

Applications:

WB, IF, IP

Name of antibody:

CCAR2

Immunogen:

Fusion protein of human CCAR2

Full name:

cell cycle and apoptosis regulator 2

Synonyms:

DBC1; DBC-1; NET35; p30DBC; p30 DBC; KIAA1967

SwissProt:

Q8N163

WB Predicted band size:

103 kDa

WB Positive control:

COS7, 3T3, C6, Jurkat, A549 and Hela cell lysates

WB Recommended dilution:

500-2000

IF positive control:

Hela cells

IF Recommend dilution:

100-200